MagForce company profile

Business Description

MagForce AG is a leading medical technology company with a focus on nanomedicine in oncology. The Company's proprietary procedure, NanoTherm® therapy, permits the targeted treatment of solid tumors by activating magnetic nanoparticles to generate heat within the tumor itself. The components of the therapy – NanoTherm®, NanoPlan®, and NanoActivator® – have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in a number of countries.

Initial listingSeptember 20, 2007
Accounting standardsHBG (German GAAP)
Fiscal year endDecember 31
Executive BoardDr. Ben J. Lipps, Prof. Hoda Tawfik, Christian von Volkmann
Supervisory BoardNorbert Neef (Chairman), Stephan Jakober, Dr. Wiebke Rösler


German Securities Identification Number (WKN)A0HGQF
Ticker SymbolMF6
Market SegmentEntry Standard
Stock ClassNo-par-value shares
Equity Capital€ 25,622,711
Outstanding Shares25,622,711 shares
Deutsche Börse listing partner and specialist, applicantSteubing AG
Designated sponsorHauck & Aufhäuser
LocationMax-Planck-Str 3, 12489 Berlin